Heart failure drug finerenone faces major test in heart remodeling trial

NCT ID NCT07270367

Not yet recruiting Disease control Sponsor: Subodh Verma Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether the drug finerenone (Kerendia) can improve heart structure and function in 156 adults with heart failure and an enlarged left ventricle. Participants take finerenone or a placebo daily for 12 months, alongside standard care. Heart changes are measured using MRI scans at the start and after one year. The goal is to see if finerenone reduces heart muscle thickening and stiffness, which could lead to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Finerenone (also known as Kerendia)
What this could lead to: If it works, this could point toward a new way to improve heart function and reduce complications in people with heart and kidney disease.
What could go wrong: This trial is still recruiting and results are not yet available. The drug may not improve heart structure more than placebo, and side effects like high potassium levels are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure Ventricular Remodeling

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Cambride Cardiac Care Centre

Cambridge, Ontario, N1R6V6, Canada
Diagnostic Assessment Centre

Toronto, Ontario, M1S4N6, Canada
North York Diagnostic and Cardiac Centre

North York, Ontario, M6B3H7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.